Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.

In today's fast-evolving pharmaceutical industry, mergers and acquisitions are critical for companies looking to expand into new areas, strengthen their portfolios, and drive innovation. But how do ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

May 1 (Reuters) - Biotech dealmaking is on pace for a bumper ⁠year ⁠in 2026, with large drugmakers on an acquisition spree ⁠to boost their pipelines ahead of upcoming patent losses. The surge appears ...

Driven by personal losses, major unmet needs and a desire to diversify from the crowded oncology market, Fosun Pharma is ...

Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved aggressively to shore up pipelines and offset looming revenue losses, according to ...

The Pharma Letter’s June M&A coverage showed that biopharma buyers remain prepared to pay heavily for late-stage or strategically useful assets, while also using smaller deals to fill technology and ...

Public markets are beginning to reopen for biotech companies after several years of muted activity. But the strongest ...

Strengthens service portfolio to meet growing demand for early-phase clinical trial support and innovation CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- Aptar Pharma, a global leader in drug delivery and ...

Well, good morning, everyone. Thank you for joining us for the year-end review and corporate update of Avicanna Inc. It's a pleasure to be hosting you this year. Giving you an update on another very ...

India’s pharmaceutical industry is witnessing a surge in global partnerships, with countries such as Switzerland, Uzbekistan, ...